

## > PGE<sub>2</sub> FPIA kit

Catalog # ADI-920-001

Fluorescence Polarization Immunoassay Kit  
For use with cell supernatants



Reagents require separate storage conditions



Check our website for additional protocols, technical notes and FAQs



For proper performance, use the insert provided with each individual kit received

### Table of Contents

<u>2</u>	<u>Introduction</u>
<u>2</u>	<u>Principle</u>
<u>3</u>	<u>Materials Supplied</u>
<u>3</u>	<u>Storage</u>
<u>3</u>	<u>Materials Needed but Not Supplied</u>
<u>4</u>	<u>Reagent Preparation</u>
<u>5</u>	<u>Sample Handling</u>
<u>5</u>	<u>Sample Recoveries</u>
<u>6</u>	<u>Assay Procedure</u>
<u>6</u>	<u>Calculation of Results</u>
<u>7</u>	<u>Typical Results</u>
<u>8</u>	<u>Performance Characteristics</u>
<u>10</u>	<u>Interferences</u>
<u>10</u>	<u>References</u>
<u>12</u>	<u>Limited Warranty</u>



FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

## Introduction

The PGE<sub>2</sub> FPIA kit is a complete kit for the quantitative determination of PGE<sub>2</sub> in buffers and culture media.

Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) is formed in a variety of cells from PGH<sub>2</sub>, which itself is synthesized from arachidonic acid by the enzyme prostaglandin synthetase<sup>1-4</sup>. PGE<sub>2</sub> has been shown to have a number of biological actions, including vasodilation<sup>5</sup>, both anti- and proinflammatory action<sup>6,7</sup>, modulation of sleep/wake cycles<sup>8</sup>, and facilitation of the replication of human immunodeficiency virus<sup>9</sup>. It elevates cAMP levels<sup>10</sup>, stimulates bone resorption<sup>11</sup>, and has thermoregulatory effects. It has been shown to be a regulator of sodium excretion and renal hemodynamics<sup>12</sup>.

Prostaglandin E<sub>2</sub>



## Principle

1. Samples and standards are added to uncoated wells.
2. A solution of PGE<sub>2</sub> covalently conjugated to fluorescein is then added to the wells.
3. A solution of monoclonal antibody to PGE<sub>2</sub> is next added. This binds, in a competitive manner, the PGE<sub>2</sub> in the standard, sample or conjugate.
4. The plate is incubated at room temperature for at least 30 minutes. The FP signal is stable for at least 20 hours.
5. The plate is then read at 520 - 535 nm, with excitation at 485 nm. The amount of signal is inversely proportional to the concentration of PGE<sub>2</sub> in the standards or samples.

## Materials Supplied

1. **PGE<sub>2</sub> FPIA Antibody**  
8 mL, Catalog No. 80-1437  
A solution of monoclonal antibody to PGE<sub>2</sub>.
2. **Assay Buffer 1 Concentrate**  
125 mL, Catalog No. 80-1435  
Tris buffered saline containing proteins and sodium azide as preservative.
3. **PGE<sub>2</sub> FPIA Conjugate Concentrate**  
0.1 mL, Catalog No. 80-1438  
A solution of fluorescein conjugated to PGE<sub>2</sub>.
4. **PGE<sub>2</sub> Standard**  
0.5 mL, Catalog No. 80-1436  
A solution of 1,000,000 pg/mL PGE<sub>2</sub>.

## Storage

All components of this kit, **except the PGE<sub>2</sub> FPIA Conjugate Concentrate and PGE<sub>2</sub> Standard**, are stable at 4°C until the kit's expiration date. The PGE<sub>2</sub> FPIA Conjugate Concentrate and PGE<sub>2</sub> Standard **must** be stored at -20°C.

## Materials Needed but Not Supplied

1. Solid black uncoated low-binding microtiter plate.
2. Foil microtiter plate sealer, if desired.
3. Fluorescence polarization detector, such as a Dynex Triad Multimode, capable of reading emissions at 520 - 535 nm, with excitation at 485 nm.



Wear gloves while using the conjugate.



Protect conjugate from light.



Reagents require separate storage conditions.

## Reagent Preparation



Protect conjugate from light.



Do not store prepared PGE<sub>2</sub> conjugate. Make fresh for each assay



Glass tubes must be used for standard preparation

### 1. Assay Buffer

Prepare the assay buffer by diluting 100 mL of the supplied Assay Buffer 1 Concentrate with 900 mL of deionized water. This can be stored at room temperature until the kit's expiration, or for 3 months, whichever is earlier. Use the diluted assay buffer for the entire assay.

### 2. PGE<sub>2</sub> Conjugate


Count the total number of wells that will receive conjugate. Use the following formula to calculate the volume of PGE<sub>2</sub> Conjugate Concentrate and the assay buffer needed to prepare PGE<sub>2</sub> conjugate.

A.  $(\text{Number of wells} + 1) \times 0.05 \text{ mL / well} = \text{Volume of assay buffer needed.}$  Increase the calculated volume to the next whole milliliter.

B.  $(\text{Volume from part A}) \times 10 \mu\text{L / mL} = \text{Volume of PGE}_2 \text{ Conjugate Concentrate needed.}$

Pipet the volume of assay buffer from part A into an amber container. From this volume, remove the volume calculated in part B. Add the calculated PGE<sub>2</sub> Conjugate Concentrate to the assay buffer. Vortex thoroughly and use.

### 4. PGE<sub>2</sub> Standards



Allow the 1,000,000 pg/mL standard stock to warm to room temperature. Label seven 12 x 75 tubes #1 through #7. Pipet 900 µL of the assay buffer into tube #1. Pipet 500 µL of the assay buffer into tubes #2 through #7. Add 100 µL of the 1,000,000 pg/mL PGE<sub>2</sub> Standard into tube #1 and vortex thoroughly. Add 500 µL of tube #1 to tube #2 and vortex thoroughly. Add 500 µL of tube #2 to tube #3 and vortex thoroughly. Continue this for tubes #4 through #7. The concentrations of PGE<sub>2</sub> in the tubes are labeled above.

**Diluted standards should be used within 60 minutes of preparation.**

## Sample Handling

The FPIA is compatible with PGE<sub>2</sub> samples in defined buffers and cell culture media. Samples diluted sufficiently into the assay buffer can be read directly from the standard curve. Samples containing some organic solvents or inherently fluorescing materials may interfere with the assay. Please refer to the Interferences section on page 10 for details.

## Sample Recoveries

PGE<sub>2</sub> standard was spiked into the following buffers, which were already diluted with the assay buffer, and measured in the kit. The results are shown below. These are the minimum dilutions required to remove the matrix interference of these solutions.

Sample	Recovery	Recommended Dilution
Hanks Buffered Saline Solution	108%	≥ neat
RPMI-1640 without phenol red	95%	≥ 1:4
RPMI-1640 with phenol red, sodium pyruvate and Essential Amino Acids	100%	≥ 1:16
RPMI-1640 with phenol red, 10% FBS and antibiotics	105%	≥ 1:32



Samples must be stored at or below -20°C to avoid loss of bioactive analyte. Repeated freeze/thaw cycles should be avoided.



Bring all reagents to room temperature for at least 30 minutes prior to opening.



All standards, controls and samples should be run in duplicate.



Make sure to multiply sample concentrations by the dilution factor used during sample preparation.

## Assay Procedure

The following procedure was used to generate all performance data cited in this publication.

1. Pipet 150  $\mu$ L of assay buffer into the Total Fluorescence (TF) wells.
2. Pipet 100  $\mu$ L of assay buffer into the Bo (0 pg/mL) wells.
3. Pipet 100  $\mu$ L of Standards #1 through #7 to the bottom of the appropriate wells.
4. Pipet 100  $\mu$ L of the samples to the bottom of the appropriate wells.
5. Add 50  $\mu$ L of the conjugate into each well.
6. Add 50  $\mu$ L of antibody into each well, except the TF wells.
7. Seal the plate with a foil plate sealer. Incubate the plate for at least 30 minutes at room temperature. The FP signal is stable for at least 20 hours.
8. Read plate on a suitable fluorescence polarization detector at 520 - 535 nm emission, with excitation at 485 nm, using the appropriate settings for that instrument.

## Calculation of Results

Several options are available for the calculation of the concentration of PGE<sub>2</sub> in samples. We recommend that the data be handled by an immunoassay software package utilizing a 4 parameter logistic curve fitting program. If data reduction software is not readily available, the concentrations can be calculated as follows:

1. Calculate the binding for each standard and sample as a percentage of the maximum binding (Bo), using the following formula:

$$\text{Percent Bound} = \frac{\text{Average mP} \times 100}{\text{Average Bo}}$$


2. Plot the Percent Bound for each standard versus PGE<sub>2</sub> concentration in each standard. Approximate a straight line through the points. The concentration of the unknowns can be determined by interpolation.

Samples with concentrations outside of the standard curve range will need to be re-analyzed using a higher dilution.

## Typical Results

The results shown below are for illustration only and should not be used to calculate results from another assay.

Sample	Net mP	Percent Bound	PGE <sub>2</sub> (pg/mL)
S1	25	10.7%	<b>100,000</b>
S2	38	16.2%	<b>50,000</b>
S3	56	23.8%	<b>25,000</b>
S4	86	36.3%	<b>12,500</b>
S5	146	61.5%	<b>6,250</b>
S6	208	87.6%	<b>3,125</b>
S7	224	94.7%	<b>1,562</b>
Unknown 1	136	57.4%	<b>7,204</b>
Unknown 2	48	20.3%	<b>27,803</b>
Bo	237	100%	<b>0</b>





For detailed cross-reactivity protocol see our website .

## Performance Characteristics

### Specificity

The cross reactivities for a number of related compounds were determined by diluting the compounds in the kit assay buffer at concentrations from 1,000,000 to 1,000 pg/mL. These samples were then measured in the PGE<sub>2</sub> FPIA, and the measured PGE<sub>2</sub> concentration at 50% B/Bo calculated. The % cross reactivity was calculated by comparison with the actual concentration of the cross reactant in the sample and expressed as a percentage.

Compound	Cross Reactivity
PGE <sub>2</sub>	100%
PGE <sub>1</sub>	100%
PGD <sub>2</sub>	11%
PGF <sub>2α</sub>	2.5%
6-keto-PGF <sub>1α</sub>	2.3%
PGB <sub>2</sub>	1.8%
PGI <sub>2</sub>	0.9%
TXB <sub>2</sub>	0.3%
Arachidonic acid	<0.1%
Dihomo-γ-linolenic acid	<0.1%

### Z-Factor

The Z-Factor is a dimensionless statistic that reflects the dynamic signal range and variation of an assay. This provides a useful parameter to evaluate the robust quality of a given assay<sup>14</sup>. The following formula was used:

$$\text{Z-Factor} = 1 - \left[ \frac{(3 \times 1\text{SD of Positive}) + (3 \times 1\text{SD of Negative})}{\text{Positive} - \text{Negative}} \right]$$

The Z-Factor of the assay was determined to be 0.88.



## Sensitivity

The sensitivity of the assay, defined as the concentration of PGE<sub>2</sub> measured at 2 standard deviations from the mean of 24 zeros along the standard curve, was determined to be 684 pg/mL.

## Linearity

A buffer sample containing PGE<sub>2</sub> was serially diluted 1:2 in the kit assay buffer and measured in the assay. The results are shown in the table below.

Dilution	Expected (pg/mL)	Observed (pg/mL)	Recovery (%)
Neat	---	76,035	---
1:2	38,017	31,610	83%
1:4	19,009	19,701	104%
1:8	9,504	11,713	123%
1:16	4,752	4,228	89%
1:32	2,376	2,329	98%

## Precision

**Intra-assay precision** was determined by assaying 24 replicates of three buffer controls containing PGE<sub>2</sub> in a single assay.

pg/mL	%CV
24,142	21
16,629	13
5,392	8.3

**Inter-assay precision** was determined by measuring buffer controls of varying PGE<sub>2</sub> concentrations in multiple assays over several days.

pg/mL	%CV
24,103	11.4
15,598	10.7
6,574	12.7

## Interferences

PGE<sub>2</sub> standard was spiked into the following solutions, which were already diluted with the assay buffer, and measured in the kit. The results were as follows:

Sample	Recovery	Recommended Percent
Methanol	107%	≤ 10%
Acetonitrile	109%	≤ 5%
2-propanol	98%	≤ 2.5%
Ethanol	106%	≤ 2.5%
DMF	104%	≤ 1.3%
DMSO	102%	≤ 1.3%

## References

1. P.W. Ramwell, Biol. Reprod., (1977) **16**: 70.
2. R.J. Flower & G.J. Blackwell, Biochem. Pharm., (1976) **25**: 285.
3. S. Moncada & J.R. Vane, Pharm. Rev., (1979) **30**: 293.
4. B. Sameulsson, et al., Ann. Rev Biochem., (1978) **47**: 997.
5. P.D.I. Richardson, et al., Brit. J. Pharmacol., (1976) **57**: 581.
6. J. Raud, et al., Proc. Natl. Acad. Sci., USA, (1988) **85**: 2315.
7. J.W. Christman, et al., Prostaglandins, (1991) **41**: 251.
8. O. Hayaishi, J. Biol. Chem., (1988) **263**: 14593.
9. S. Kuno, et al., Proc. Natl. Acad. Sci., USA, (1986) **83**: 3487.
10. D.L. Bareis, et al., Proc. Natl. Acad. Sci., USA, (1983) **80**: 2514.
11. L.G. Raisz, et al., Nature, (1977) **267**: 532.
12. C.R. Long, et al., Prostaglandins, (1990) **40**: 591.
13. National Committee for Clinical Laboratory Standards Evaluation Protocols, SC1, (1989) Villanova, PA: NCCLS.
14. J. Zhang, et. al., J.Biomol. Screening, (1999) **4** (2): 63-73.

## Notes



MSDS (Material Safety Data Sheet) available online

### USE FOR RESEARCH PURPOSES ONLY

Unless otherwise specified expressly on the packaging, all products sold hereunder are intended for and may be used for research purposes only and may not be used for food, drug, cosmetic or household use or for the diagnosis or treatment of human beings. Purchase does not include any right or license to use, develop or otherwise exploit these products commercially. Any commercial use, development or exploitation of these products or development using these products without the express written authorization of Enzo Life Sciences, Inc. is strictly prohibited. Buyer assumes all risk and liability for the use and/or results obtained by the use of the products covered by this invoice whether used singularly or in combination with other products

### LIMITED WARRANTY; DISCLAIMER OF WARRANTIES

These products are offered under a limited warranty. The products are guaranteed to meet all appropriate specifications described in the package insert at the time of shipment. Enzo Life Sciences' sole obligation is to replace the product to the extent of the purchasing price. All claims must be made to Enzo Life Sciences, Inc., within five (5) days of receipt of order. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF OTHERS, AND ALL SUCH WARRANTIES (AND ANY OTHER WARRANTIES IMPLIED BY LAW) ARE EXPRESSLY DISCLAIMED.

### TRADEMARKS AND PATENTS

Several Enzo Life Sciences products and product applications are covered by US and foreign patents and patents pending.

#### **Global Headquarters**

##### **Enzo Life Sciences Inc.**

10 Executive Blvd  
Farmingdale, NY 11735  
(p) 1-800-942-0430  
(f) 1-631-694-7501  
(e) info-usa@enzolifesciences.com

##### **Enzo Life Sciences (ELS) AG**

Industriestrasse 17, Postfach  
CH-4415 Lause / Switzerland  
(p) +41/0 61 926 89 89  
(f) +41/0 61 926 89 79  
(e) info-ch@enzolifesciences.com

Please visit our website at [www.enzolifesciences.com](http://www.enzolifesciences.com) for additional contact information.

